Veru Inc. $VERU Shares Sold by Envestnet Asset Management Inc.

Envestnet Asset Management Inc. lessened its holdings in shares of Veru Inc. (NASDAQ:VERU) by 7.0% in the second quarter, according to its most recent filing with the SEC. The firm owned 619,661 shares of the company’s stock after selling 46,633 shares during the quarter. Envestnet Asset Management Inc. owned about 0.42% of Veru worth $361,000 as of its most recent SEC filing.

Other institutional investors and hedge funds also recently modified their holdings of the company. MPM Bioimpact LLC increased its holdings in shares of Veru by 53.8% during the first quarter. MPM Bioimpact LLC now owns 6,592,727 shares of the company’s stock valued at $3,231,000 after purchasing an additional 2,307,362 shares during the period. Choreo LLC grew its position in Veru by 67.4% in the 1st quarter. Choreo LLC now owns 669,277 shares of the company’s stock valued at $328,000 after buying an additional 269,500 shares in the last quarter. Nuveen LLC acquired a new position in Veru during the 1st quarter valued at about $88,000. Sender Co & Partners Inc. bought a new stake in shares of Veru during the 1st quarter worth about $64,000. Finally, Charles Schwab Investment Management Inc. lifted its stake in shares of Veru by 21.0% in the 1st quarter. Charles Schwab Investment Management Inc. now owns 375,291 shares of the company’s stock worth $184,000 after acquiring an additional 65,045 shares during the period. Institutional investors own 47.16% of the company’s stock.

Veru Price Performance

VERU stock opened at $2.44 on Thursday. The firm has a market cap of $35.77 million, a PE ratio of -1.11 and a beta of -0.80. Veru Inc. has a 12 month low of $2.11 and a 12 month high of $14.20. The firm has a 50 day simple moving average of $3.36 and a 200 day simple moving average of $4.40.

Analyst Upgrades and Downgrades

A number of research analysts recently commented on the stock. Raymond James Financial lowered their price objective on shares of Veru from $30.00 to $20.00 and set an “outperform” rating on the stock in a research note on Wednesday, August 13th. Weiss Ratings reiterated a “sell (e+)” rating on shares of Veru in a research report on Wednesday, October 8th. Two equities research analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the company. According to MarketBeat.com, Veru has an average rating of “Hold” and a consensus price target of $25.00.

Veru Company Profile

Veru Inc, a late clinical stage biopharmaceutical company, focuses on developing medicines for treatment of metabolic diseases, oncology, and acute respiratory distress syndrome (ARDS). Its marketed products comprise FC2 female condom for the dual protection against unplanned pregnancy and the transmission of sexually transmitted infections.